Tempus AI

What a year it has been! There have been so many milestones and achievements across the the business, and we are thankful for our whole team, as well as our provider and research partners for making this progress possible. Join us in a #YearInReview at Tempus below: 

We're excited to announce that we now have in-network provider status with Blue Cross and Blue Shield of Illinois, Blue Shield of California, and Avalon Healthcare Solutions. As part of the agreement with Avalon, we are a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, and CareSource in four markets. Now, as an in-network laboratory, our collection of assays can be applied to optimize patients’ care and may lead to lower out-of-pocket costs for patients who receive any such testing in accordance with their individual plan. Learn more: https://tempus.co/41FWukN

We're excited to share the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. This milestone allows us to more broadly support clinicians in identifying patients at increased risk of atrial fibrillation/flutter. To learn more about EGG-AF and its intended use, visit here: https://tempus.co/4flAij9

Tempus offers personalized treatment across the breast cancer continuum. Visit Booth #1347 at #SABCS24 to learn more about our comprehensive offerings for your breast cancer patients: https://tempus.co/4ivSZUc

Stop by Booth #1347 at #SABCS24 to discover how we are leveraging AI and technology to advance precision oncology for breast cancer patients. Experience live demos of our AI-enabled technologies such as One, Hub and Lens for providers, biopharma, and research partners. Learn more: https://tempus.co/3Bmscc9 San Antonio Breast Cancer Symposium

We're pleased to be presenting four abstracts during #SABCS24. This research includes a Poster Spotlight Presentation which highlights that the dual solid tumor + liquid biopsy approach demonstrates a strategy for enhancing patient care by improving diagnostic yield while simultaneously decreasing the potential financial burden of unnecessary procedures. Find more information and presentation times here: https://tempus.co/3Bmscc9

We’re excited to be at #SABCS24 this week in San Antonio! Visit Booth #1347 to meet with our team, explore our comprehensive offerings for your breast cancer patients, and learn more about our research. Find more information, including research presentation times here: https://tempus.co/3OPp9fA

A recent case study highlights how our noninvasive imaging techniques allow for the continuous study of the same organoids across various assays, preserving their viability for longitudinal analysis and multiplexed testing. Read here: https://tempus.co/4ilpZyt

We’re excited to be at #ASH24 in San Diego starting this weekend! Stop by booth #3400 to meet with our team and learn more about our work in the hematology space. Find more information here: https://tempus.co/4giBzIx

We're honored to be included in Fortune's Future 50 list. Tempus is ranked #22 amongst a variety of innovative companies best poised to continuously evolve and grow.